Z-1240-2023 Class II Ongoing

Recalled by Becton Dickinson & Company — Franklin Lakes, NJ

FDA device recall Z-1240-2023 was initiated by Becton Dickinson & Company on Feb 1, 2023 and is designated Class II. Reason for recall: Nonsterile syringe potentially exposing the patient to pathogenic microorganisms and a risk of local infection. The recall status is ongoing. Affected quantity: 1,129,000 units.

Recall details

Product Type
Devices
Report Date
Mar 22, 2023
Initiation Date
Feb 1, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,129,000 units

Product description

BD Ultra-Fine Insulin Syringe 0.5mL, 8mm, 31G-Insulin Syringes are designed for administering insulin in the treatment of diabetes mellitus. Catalog Number: 326713

Reason for recall

Nonsterile syringe potentially exposing the patient to pathogenic microorganisms and a risk of local infection.

Distribution pattern

Worldwide distribution - US Nationwide and the countries of Chile, Colombia, Dominican Republic, Bahamas, Panama, Peru, Mexico, El Salvador, Mexico, Malaysia, Philippines, Vietnam, Hong Kong, Taiwan, Thailand, Canada.

Code information

GTIN: N/A Lot Number: 2038580, Exp. Date: 20270531; Lot Number: 2063298, Exp. Date: 20270531; Lot Number: 2137904, Exp. Date: 20270731

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1240-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1240-2023. Report a data issue: hello@regdatalab.com.